Asthma is a type of chronic respiratory disease, which is characterized by attacks of breathlessness and wheezing. Asthma can occur at any stage, though it is the most common disease in children. Asthma attacks are linked to respiratory infections and environmental factors such as allergens, tobacco, smoke, and indoor and outdoor pollution. Indoor pollution factors include mold, chemicals, strong odors, and house dust whereas outdoor pollution factors include air pollution, allergens, tobacco, and smoking. Such factors are responsible for development and exacerbation of asthma.
Restraints of the Global Asthma and COPD Market
Major factors hampering the growth of the asthma and COPD market during the forecast period constitutes of patent losses, and high costs.
Key features of the study:
- This report provides in-depth analysis of the global asthma and COPD market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019–2027), considering 2018, as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
- It profiles leading players in the global asthma and COPD market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include AstraZeneca, Novartis AG, GlaxoSmithKline plc, Merck & Co., Verona Pharma plc,, Regeneron Pharmaceuticals, Inc., GlaxoSmithKline plc, and Boehringer Ingelheim GmbH.
- Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
- The global asthma and COPD market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.
Detailed Segmentation
- Global Asthma and COPD Market, By Drug Type:
- Bronchodilators
- Short Acting Bronchodilators
- Long Acting Bronchodilators
- Anticholinergics
- Anti-Inflammatories
- Inhaled Corticosteroids
- Anti-Leukotriene
- Monoclonal Antibodies
- Combination Therapies
- Global Asthma and COPD Market, By Disease Type:
- Global Asthma and COPD Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
- Global Asthma and COPD Market, By Geography:
- North America
- By Drug Type
- Bronchodilators
- Short Acting Bronchodilators
- Long Acting Bronchodilators
- Anticholinergics
- Anti-Inflammatories
- Inhaled Corticosteroids
- Anti-Leukotriene
- Monoclonal Antibodies
- Combination Therapies
- By Disease Type
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
- By Country:
- Europe
- By Drug Type
- Bronchodilators
- Short Acting Bronchodilators
- Long Acting Bronchodilators
- Anticholinergics
- Anti-Inflammatories
- Inhaled Corticosteroids
- Anti-Leukotriene
- Monoclonal Antibodies
- Combination Therapies
- By Disease Type
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
- By Country:
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Drug Type
- Bronchodilators
- Short Acting Bronchodilators
- Long Acting Bronchodilators
- Anticholinergics
- Anti-Inflammatories
- Inhaled Corticosteroids
- Anti-Leukotriene
- Monoclonal Antibodies
- Combination Therapies
- By Disease Type
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
- By Country:
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- By Drug Type
- Bronchodilators
- Short Acting Bronchodilators
- Long Acting Bronchodilators
- Anticholinergics
- Anti-Inflammatories
- Inhaled Corticosteroids
- Anti-Leukotriene
- Monoclonal Antibodies
- Combination Therapies
- By Disease Type
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East:
- By Drug Type
- Bronchodilators
- Short Acting Bronchodilators
- Long Acting Bronchodilators
- Anticholinergics
- Anti-Inflammatories
- Inhaled Corticosteroids
- Anti-Leukotriene
- Monoclonal Antibodies
- Combination Therapies
- By Disease Type
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Drug Type
- Bronchodilators
- Short Acting Bronchodilators
- Long Acting Bronchodilators
- Anticholinergics
- Anti-Inflammatories
- Inhaled Corticosteroids
- Anti-Leukotriene
- Monoclonal Antibodies
- Combination Therapies
- By Disease Type
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
- By Country/Region:
- Central Africa
- South Africa
- North Africa
- Company Profiles
- AstraZeneca PLC*
- Company Overview
- Product Portfolio
- Financial Performance
- Key Strategies
- Recent Developments
- Novartis AG
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Verona Pharma plc
- Regeneron Pharmaceuticals, Inc.
- Boehringer Ingelheim GmbH
“*” marked represents similar segmentation in other categories in the respective section.
Table of Content - Asthma And Copd Market
